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sychiatric side effects (PSEs) can be induced by
the pharmacological treatment of physical illnesses.The
clinical presentation of PSEs often resembles sponta-
neous psychiatric syndromes (ie,noniatrogenic,naturally
occurring diseases). PSEs can occur at usual doses, in
cases of intoxication,or during the days following with-
drawal of a given treatment.PSEs range from short-last-
ing anxiety to severe confusion,and alleged cases of sui-
cide have even been reported.
The Diagnostic and Statistic Manual of Mental Disorders,
Fourth Edition (DSM-IV)
1 defines some dozens of cate-
gories of PSE,according to the disorder and to the incrim-
inated substance,eg,“persisting dementia induced by seda-
tives, hypnotics or anxiolytics.”The DSM-IV categories
include drugs for therapeutic purposes,medication taken
abusively, and other substances. The International
Classification of Diseases
2 is very similar to DSM-IV in its
categorization,with minor differences in terms of category
codes.
The challenge of PSEs in everyday practice is the diffi-
culty in recognizing these frequent and potentially dan-
gerous situations.The diagnosis of PSEs raises the same
questions as the diagnosis of any psychiatric sign or
symptom,which means that the clinician has to consider
a rather long list of differential diagnoses.The following
concepts refer to PSEs,as well as to other kinds of side
effects:
• Exposure:The period of time the patient received the
drug suspected of inducing a side effect.
• Dechallenge:The interruption of the suspected med-
ication,regardless of the remission of adverse effects.
Positive dechallenge means that remission was tempo-
rally associated with the interruption of medication.
• Rechallenge:The reintroduction of the suspected drug.
Positive rechallenge means that symptom reappearance
was temporally associated with suspected drug rein-
troduction.
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A drug can be considered to have a high probability of
causing side effects in cases of positive exposure,with a
positive dechallenge and a positive rechallenge.
The importance of PSEs relates to the potential harm of
these side effects and to their high incidence.Two exam-
ples are reserpine and corticosteroids.Reserpine,when
it was prescribed, may have caused mood disorders in
10% of treated subjects.With corticosteroids,6% of all
patients develop some PSEs.
3
The focus of this review is on depression, anxiety, and
psychotic states, but a few other PSEs are also men-
tioned.A summary of the PSEs is presented and some
examples are given in detail.In addition,diagnostic issues
are discussed to facilitate identification of PSEs in inter-
nal medicine.PSEs secondary to psychotropic medica-
tion (such as antidepressants,anxiolytics,antipsychotics,
or mood-stabilizing agents) are not described here.They
probably induce more PSEs than the compounds quoted
here,since they act directly on the nervous system.
Mechanisms of PSEs
As with any side effect,pharmacological mechanisms are
divided according to their pharmacokinetic or pharmaco-
dynamic nature.Patient-specific factors also lead to PSEs.
Pharmacodynamic mechanisms
Medications used in the treatment of physical disorders
can modify neurotransmitter systems (as do psychotropic
medications).These modes of action can imply a direct
influence on neurotransmitters,as is the case for dopamin-
ergic agents in the treatment of Parkinson's disease.
Interleukin (IL) treatment is another example where there
is a direct influence,since interleukins are involved in neu-
rotransmission as well as in many other bodily functions.
Other nonpsychotropic medications influence neuro-
transmitter systems in a more indirect manner,such as cor-
ticosteroids or sex steroids.
It is interesting to compare the mode of action of nonpsy-
chotropic medications with what is known concerning the
postulated pathophysiology of psychiatric disorders.
Indeed,the mechanisms of PSEs are sometimes compat-
ible with a given hypothesis for the corresponding spon-
taneous syndromes.For example,the occurrence of hal-
lucinations and delusions on dopamine agonists (eg,
levodopa) is clearly within the domain of the dopamin-
ergic hypothesis for schizophrenia.In this case,there is a
clear relationship between the hypothesis for a disease
and the postulated mechanisms of a side effect. In
another example, that of depression as a side effect of
interferons (IFNs),the relationship is not so easily iden-
tifiable. Stress and depression are associated with
increased circulating concentrations of cytokines such as
IL-1β,IL-6,γ-IFN,and positive acute-phase proteins,and
hyperactivity of the hypothalamus-pituitary-adrenal axis.
Immunological activation induces “stress-like” behav-
ioral and neurochemical changes in animals.
4An associ-
ation of the cerebrospinal fluid (CSF) concentration of
proinflammatory cytokines and major depressive disor-
ders was reported in depressed patients with higher CSF
concentrations of IL-1β, lower IL-6, and no change in
tumor necrosis factor α (TNF-α).
5A positive correlation
was found between serum IL-1β and the severity of
depression.Other studies suggest that antidepressants
can act on neouroimmunomodulation, and have been
shown to shift the cytokines toward a decreased produc-
tion of proinflammatory cytokines.
6
Pharmacokinetic mechanisms
Pharmacokinetic mechanisms are relevant when the PSE
is known to follow a dose–response curve.A low clearance
represents the main pharmacokinetic mechanism induc-
ing PSEs, ie, other changes in the pharmacokinetics of
drugs are of little relevance.Disease states,hepatic enzyme
polymorphisms,and drug interactions leading to metabolic
inhibition are the main reasons for a low clearance.
Interaction by metabolic inhibition is a general principle,
applicable not only to PSEs,but also to other side effects.
Many drugs inhibit one or more pathways of hepatic
metabolism.Cytochrome P-450 (CYP450) enzymes metab-
olize endogenous as well as a variety of exogenous sub-
strates,such as toxins and drugs.Some drugs are metabo-
lized by one metabolic pathway,others by many.When all
metabolic pathways of a medication are inhibited,then the
concentration of this drug will rise,favoring the occurrence
of side effects.
Antifungals can inhibit some metabolic pathways,includ-
ing those of mefloquine,ie,the 3A4 isoenzyme of CYP450.
7
Mefloquine can rarely lead to serious PSEs at prophylac-
tic doses,
8,9 but these risks are greater at high plasma con-
centrations.
10The prescription of a macrolide antibiotic will
probably raise concentrations of mefloquine, as most
macrolides are 3A4 inhibitors. Hence, serious PSEs can
occur even at usual doses of both drugs.Risk factors
Patient-specific mechanisms of PSEs are more precisely
defined as patient-related risk factors.The risk factors for
developing PSEs can be medication-related or patient-
related,as shown in Table I.
Polypharmacy is one of the most important iatrogenic risk
factors for PSEs,because of the addition of pharmacolog-
ical effects or due to metabolic inhibition.Addition of phar-
macological effects is illustrated by the concomitant pre-
scription of clozapine and biperiden.These drugs are both
potent anticholinergics,so the risk of anticholinergic side
effects is greater when they are taken together than with
each medication taken alone.Polypharmacy mimics a slow
metabolizer picture for many drugs,when hepatic metab-
olism is inhibited.There are many inhibitors of hepatic
metabolism:omeprazole,cimetidine,antifungals,antivirals,
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A)
reductase inhibitors (statins),antihypertensives,antiepilep-
tics,antidepressants,grapefruit juice,and many other com-
pounds. It is practically impossible to memorize all the
CYP450 isoenzyme substrates, inhibitors, and inducers.
Hence pocket tables
11 and software
12,13 are useful for obtain-
ing rapid information about such drug–drug interactions,
and potentially avoiding induction of PSEs.Many PSEs are
dose-dependent, so their risk increases with factors that
raise the concentration of drugs.The CYP450 2D6 isoen-
zyme has absent or impaired activity in 7% of
Caucasians
14,15 and the 2C19 activity is absent or impaired
in as many as 12% to 22% of Asians.
15
Diagnosis and differential diagnosis
The diagnosis of PSEs can be challenging.The clinical pre-
sentations of depressive,anxious,or psychotic PSEs meet
most criteria of the DSM-IV for the corresponding spon-
taneous (noniatrogenic) syndromes.Therefore,almost any
psychiatric symptom or syndrome could be considered as
a potential PSE,until one has proven the contrary.
A simple case would be that of a peculiar or unusual psy-
chiatric symptom,observed in a person who has started
(or interrupted) a medical treatment recently and has no
history of a previous psychiatric decompensation and no
evident susceptibility to develop such a decompensation.
A difficult case would be that of a person who has already
suffered from many decompensations of psychiatric dis-
orders and who develops a recurrence that presents itself
clinically in a similar manner as that known for the sub-
ject.In this case,a PSE can easily be overlooked,ie,the
role of a medical treatment as a relevant factor is difficult
to identify.Another case is that of a physical disorder that
can also induce psychiatric signs.For example,the clini-
cian might not be able to determine whether a case of
depression relates to the patient’s multiple sclerosis or to
the corticosteroid treatment.Another example would be
a malaria patient treated with mefloquine and presenting
delirium:is the delirium due to the malaria rather than to
the mefloquine? 
The fact of being hospitalized for a severe physical illness
constitutes a strain:in an intensive care unit,the patient is
exposed to pain,sleep deprivation,unusual environment,
and threat of disability or even death.In this context,it is
difficult to distinguish reactive or drug-induced psycho-
logical signs. Complex medical cases receive polyphar-
macy: some patients can receive antiarrhythmics, bron-
chodilatators,analgesics,antibiotics,benzodiazepines,and
other medications.Among these complex situations,it can
become practically impossible to determine a single cause
for a PSE.Yet,making such a diagnosis is necessary.For
example,in systemic lupus erythematosus,the occurrence
of PSEs can be due to corticosteroid treatment,but also to
the lupus cerebritis;the latter is associated with high lev-
els of antibodies to P ribosomal proteins,in both CSF and
serum.
16 This differential diagnosis is relevant, since the
corticosteroid dose may need to be increased.
The differential diagnoses of PSEs are summarized in
Table II.History and chronology of drug administration
are first-line tools to diagnose a PSE.As already men-
tioned,an anamnesis with a positive exposure,positive
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Table I. Risk factors for psychiatric side effects (PSEs).
Medication-related PSEs
Polypharmacy
High doses
Route of administration (eg, intravenous or intrathecal)
Faster administration (by any route)
Narrow therapeutic index
Patient-related PSEs
Present or past mental illnesses
Hepatic insufficiency, slow metabolizer, 
and other metabolic conditions
Augmented permeability of the blood-brain barrier
(eg, meningitis or porphyria)
Very young or elderly patients
Postpartum
Other situations of stress (eg, intensive care unit)dechallenge, and positive rechallenge, indicates a high
probability of a causal link between a psychiatric sign and
a prescribed medication.
A PSE can differ from a spontaneous psychiatric syn-
drome in duration,since the duration of the PSE is more
linked to the presence or withdrawal of the offending
agent.Once the incriminated treatment is interrupted,
behavioral symptoms usually remit within days to weeks,
depending on the half-life of the substance or the pres-
ence of a withdrawal syndrome. In complex cases of
polypharmacy, if the chronology of medication cannot
help determine which medication caused the side effect,
a trial could be done by replacing one of the suspected
drugs by another with a lesser risk of PSEs.
Another issue about chronology concerns what can occur
after interruption of treatment.This can be illustrated by
the case of an elderly male patient, who took St John’s
wort for 4 months,with partial improvement of his depres-
sion.The dose was gradually increased,but without a com-
plete remission of the depression.Travel to an endemic
zone of malaria was planned and mefloquine prophylaxis
was introduced.No side effect occurred during the first 10
days,until the clinician decided to replace St John’s wort
by citalopram, without changes in the mefloquine pro-
phylaxis.The patient rapidly developed hallucinations after
the introduction of citalopram.He had no mental status
changes when he received St John’s wort and mefloquine,
so the clinician stopped citalopram.The hallucinations per-
sisted.When mefloquine was discontinued,the hallucina-
tions remitted.The message is that even the interruption
of a drug can lead to an increase in the plasma concentra-
tions of another drug,causing side effects.St John’s wort
induces mefloquine metabolism,which means that,in this
case, mefloquine concentrations were lower while St
John’s wort was given. Hallucinations are known side
effects of mefloquine.
To improve the detection of PSEs,the physician should
look for the anamnestic key factors listed below:
• Dates of occurrence of psychiatric symptoms suspected
of being side effects.
• Dates of medication exposure,dechallenge,and rechal-
lenge.
• Previous psychiatric history.
• If polypharmacy is given,dates of introduction or dis-
continuation of other drugs.
• Dates of factors worsening existing comorbidities.
• Plasma concentration measurements.
The most useful complementary examination for PSE
investigation is generally the monitoring of plasma con-
centrations of suspected medications.Monitoring of drug
concentration is frequently performed for some drugs
with high risk of toxicity,eg,digoxin,theophylline,or lido-
caine.Many other compounds can also be dosed in spe-
cialized laboratories.
If past analyses were performed for a given patient,they
may also provide valuable clues.This may apply even if dif-
ferent medications were measured.This occurs because an
abnormally high concentration of a medication may sug-
gest a weak or absent metabolic pathway,as discussed in
the mechanisms section above.Knowledge of the patient’s
deficiencies in metabolism allows avoidance of some PSEs
by future prescriptions.Genotyping is a complementary
examination to detect polymorphisms of hepatic enzymes.
Description of psychiatric side effects
Table III
3,8,9,17-197 gives a list of medications that might
induce depression, mania, anxiety, or psychotic syn-
dromes (defined by delusions and/or hallucinations).This
information is qualitative,in the sense that the severity
or the frequency of these side effects under each med-
ication or class is not indicated.Specific information can
be found in the bibliography.Some psychotropics,such
as benzodiazepines,are listed in Table III because they
are frequently prescribed in internal medicine.Obviously,
more than one of these PSEs can occur in a given patient.
For example,many depressive states are accompanied by
anxiety.Some clinically relevant examples of medications
presented in Table III are discussed below in more detail.
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Table II. Differential diagnoses of psychiatric side effects (PSEs) of med-
ications.
Diagnoses other than medication side effects
Underlying physical illnesses with psychiatric symptoms 
(eg, multiple sclerosis, systemic neoplasias, electrolytic 
disturbances, lupus erythematosus)
Aggravation of an existing psychiatric illness
Inaugural psychiatric decompensation in individuals with 
no evident susceptibility
Differential diagnoses among PSEs
PSEs at usual doses
Withdrawal-related PSEs. Side effects can occur after the 
discontinuation of antiparkinsonian agents, 
benzodiazepines, antipsychotics, antidepressants, 
anabolic androgen steroids, etc
Intoxication-related PSEsMefloquine and chloroquine
Mefloquine, which is prescribed for the prophylaxis or
treatment of malaria,frequently causes PSEs.These PSEs
can be severe: psychosis, delusion, and even suicidal
ideation.Disabling PSEs occur in less than 1% of patients
under mefloquine at therapeutic doses, and in less than
1:10 000 under mefloquine prophylaxis.This indicates that
the PSEs are dose-related.However,suicide attempts have
even been reported at prophylactic doses.
158,159 Mefloquine
PSEs may begin some hours after the first dose.
8,160Their
mechanism is not clearly understood; actions as a N-
methyl-D-aspartate (NMDA) receptor antagonist or on
sigma receptors have been proposed.Chloroquine,another
antimalarial,also produces psychiatric and neurological
side effects:agitation,aggressiveness,amnesia,confusion,
depression,hallucinations,and mania.Psychiatric changes
under chloroquine may develop insidiously.Memory or
perception changes can be the only clues to side effects in
this developing phase.The half-life of chloroquine is long
at around 1 month.Therefore,remission of a chloroquine-
related PSE may take days.Children appear to be at great-
est risk to psychosis under chloroquine treatment.
81
Metronidazole
The common side effects of metronidazole are confusion,
paresthesia,dizziness,vertigo,and syncope.Seizures and
encephalopathy are rare.Psychotic symptoms have also
been described.
170,171 Brain toxicity can occur at usual doses
of metronidazole.However,at larger or chronic doses,an
increased prevalence (as high as 25%) has been observed.
An interaction between metronidazole and alcohol,simi-
lar to the disulfiram effect, was first described in the
1960s,
172 and many publications on this topic followed.One
death has been attributed to this interaction.
173This PSE
was believed to result from a metronidazole blockade of
hepatic aldehyde dehydrogenase,an enzyme in the metab-
olism of ethanol,followed by the accumulation of acetalde-
hyde in the blood.However,these early publications have
been called into question.
174A placebo-controlled study
197
found no effect on blood acetaldehyde concentrations
when 12 subjects ingested metronidazole with ethanol;it
induced no objective or subjective disulfiram-like effects.
Isotretinoin
The Food and Drug Administration (FDA) has received
reports of depression and suicide attempts in patients
treated with isotretinoin. The authors who commented
these cases
132 affirm that “factors suggesting a possible asso-
ciation between isotretinoin and depression include a tem-
poral association between use of the drug and depression,
positive dechallenges (often with psychiatric treatment),
positive rechallenges, and possible biologic plausibility.
Psychiatric side effects of medications - Casagrande Tango Dialogues in Clinical Neuroscience - Vol 5 . No.2 . 2003
159
Table III. Psychiatric side effects potentially induced by pharmacological
treatment.
Depression Mania Anxiety Psychotic
symptoms
Amantadine
17-22 XX X X
Aminoglycosides
23,24 X
Amphetamines
25-30  XX X X
Anabolic steroids
31-33 XX X X
Anesthetics
21,22,34,35 XX
Anticholinergics
21,36-39 XX X
Antihistamines
21,22,40 XX
Antitubercular agents
22,41-45XX X
Antivirals
46-53 XX X
Baclofen
22,54-58 XX X X
Barbiturates
22,59 XX X X
Benzodiazepines
21,22,60-62 XX X
β-Blockers
21,22,63-72 XX X X
Bromocriptine
21,73-77 XX X
Cephalosporins
22,78-80 XX
Chloroquine
81-88 XX X X
Clonidine
21,22,89-93 XX X X
Corticosteroids
3,21,22,94-112 XX X X
Digoxin
21,22,113-115 XX X
Disulfiram
21,22,116-118 XX X X
Interferon-α
22,119-131 XX X X
Isotretinoin
22,132-137 XX
Levodopa
21,22,138-152 XX X X
Lidocaine
153-157 XX X X
Mefloquine
8,9,22,158-160 XX X X
Methyldopa
21,22 XX X
Methylphenidate
22,161-163 XX X
Metoclopramide
21,22,164-169 XX X
Metronidazole
22,170-175 X
Opioids
21,22,176-181 XX X X
Oral contraceptives
21,22,182,183XX
Procainamide
21,184-188 XX X X
Pseudoephedrine
22,189-192 XX
Quinidine
21,22,193,194 XX
Quinolones
22,195 XX X
Thiazide diuretics
22,196 XCompared with all drugs in the FDA’s Adverse Event
Reporting System database to June 2000, isotretinoin
ranked within the top 10 for number of reports of depres-
sion and suicide attempt.”An American drug database
198
also warns that isotretinoin “may cause depression,psy-
chosis and,rarely,suicidal ideation,suicide attempts,sui-
cide, and aggressive and/or violent behaviors.” Despite
some publications contrary to this association,
199,200 the pos-
sibility of depression and suicidal ideation should be taken
into account when prescribing isotretinoin.Establishing a
causality link between isotretinoin and these PSEs can be
complex.Most isotretinoin-treated patients are young,and
young people are also at greater risk for depression.
Another aspect is that disfiguring dermatological condi-
tions could be associated with a greater prevalence of
depression and suicidal ideation,
201 while isotretinoin
improves the aspect of patients suffering from severe forms
of acne.The improvement in these severe forms of acne
after isotretinoin treatment may reduce anxiety and
depression.
202
Interferons
IFN-α is prescribed in viral hepatitis and in some neo-
plasias; IFN-β is prescribed in multiple sclerosis and
hepatitis. Frequent side effects limit their use. IFN-α
induces more PSEs than IFN-β. Psychiatric manifesta-
tions of IFNs are depression,personality disorders,panic
attacks,other anxiety states,manic and psychotic symp-
toms,
119 impulsiveness,and aggressive behavior.
203 More
than 10% of patients receiving IFN-α manifest PSEs.
120-122
Depressive states related to IFNs usually occur in the first
weeks of treatment.They are more prevalent and severe
in people who also suffered from depression before IFN
treatment.Suicidal behavior is an alleged side effect of
IFN-α.
123-127 IFN-α–related depression or suicidal behav-
ior may continue after interruption of treatment.
123,126This
feature has rarely been attributed to IFN-β.
50,204 Since sui-
cide attempts were described after withdrawal of IFN-α,
even without a depressive episode during the treatment,
some authors
123 advise psychiatric supervision “even more
frequently after interferon withdrawal.”
A randomized controlled trial
121 found a favorable effect
upon the prescription of a selective serotonin reuptake
inhibitor (SSRI) as prophylaxis of depression in patients
who are programmed to receive IFN-α. SSRIs are also
useful for treatment of depression,
128 once IFN-α is
started. Paroxetine is the most studied,
121,128 but other
SSRIs,such as sertraline,
129 citalopram,
130 fluoxetine,
131 and
fluvoxamine may also be effective.There is no consensus
on whether SSRIs should be given as prophylaxis for all
patients programmed to receive IFN-α or only to those
who develop depression.
Corticosteroids
Corticosteroid treatment may lead to many PSEs. The
most frequent PSEs are depression,mania,anxiety,insom-
nia,delusions (paranoia or other themes),hallucinations,
agitation,and confusional states.Rarer ones include seri-
ous heteroaggressivity,disturbances of consciousness,and
depersonalization.
3,95,205These PSEs can start after just 1
day of treatment.In more than half of patients,side effects
usually remit after interruption of corticosteroids.
206
However,side effects can also occur during the withdrawal
period, eg, anhedonia and fatigue may last several
weeks.
207,208The risk of PSEs is high:about 6% of patients
manifest some PSEs. Prednisone is the most implicated
corticosteroid,but PSEs were also described with methyl-
prednisolone, dexamethasone, and beclomethasone. A
dose–response effect is clearly seen with prednisone:doses
greater than 40 mg/day are related to greater psychiatric
morbidity. Moreover, hypoalbuminemia leads to an
increase in plasma prednisone free fraction, potentially
increasing the amount of prednisone that reaches brain.
Hence, hypoalbuminemia might be associated with an
increase in PSE incidence,but this has not been confirmed.
Small neuroleptic doses can lead to a favorable response
of corticosteroid PSEs in some days.
94,206Treatment with
lithium may be helpful.
94 Prophylaxis of corticosteroid
PSEs with lithium
96-98 or valproate
99 has been described,but
these approaches can be harmful to patients on corticos-
teroids who might not develop PSEs. Patients on corti-
costeroids should be monitored for psychiatric and cogni-
tive side effects.
31
Anabolic androgen steroids
Anabolic androgen steroids (testosterone and its synthetic
derivatives) are associated with a number of PSEs:impul-
siveness,irritability,and belligerence (“steroid rage”),delu-
sions,hypersexuality,auditory and visual hallucinations,
and dependence.
31 Mania,hypomania,and major depres-
sion have been significantly associated with exposure to
steroids.
32 PSEs due to anabolic androgen steroids are
mostly seen in abusive users.These PSEs relate to drug
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lated with anabolic androgen intake and major depression
follows its withdrawal.
31 In chronic users of slow-liberation
forms, lassitude or depression may be seen just before
administration of the next dose.The abuse of anabolic
androgen steroids seems prevalent among teenagers wish-
ing to increase muscular mass.It was found in subjects as
young as 9 years old,
209 with a possible peak at ages 15 and
16.
210 In another study,with a sample of 12 000 American
high-school students, a prevalence of 4% was found in
young males.
211 Steroid users often seek medical care for
the acne these medications induce or exacerbate.If family
members complain of aggressiveness and mood changes
(which are less noticed by the users themselves),the clin-
ician might suspect of anabolic androgen abuse,especially
in teenagers of male sex.
β-Adrenergic antagonists (β-blockers)
Depression,nightmares,and sexual dysfunction are com-
monly reported PSEs of β-blockers.Hallucinations have
been attributed to propranolol.
63-68With oral administra-
tion,depression and agitation related to propranolol might
be dose-dependent.
69 Ophthalmic preparations of β-block-
ers may also induce these PSEs,eg,timolol.
70Withdrawal
reactions to β-blockers can occur even with ophthalmic
presentations;cases of rebound tachycardia were reported
after ophthalmic timolol interruption.It has long been rec-
ognized that β-blockers cause psychiatric and sexual side
effects.However,this has become controversial,according
to recent studies.In a placebo-controlled trial,the authors
found no difference between propranolol and placebo
groups for the occurrence of depressive symptoms or sex-
ual dysfunction.
212A later review stated that “β-blockers
have no significant increased risk of depressive symptoms
and only small increased risks of fatigue and sexual dys-
function.”
213 Nevertheless,it could be that the risk of sui-
cide increases in users of β-blockers.
71 The conflicting
results on β-blocker depression suggest that some may
improve depression (eg,pindolol),others may worsen it,
and others may have little effect.
214
Conclusion
This review shows that drug-induced PSEs may occur
with several medications prescribed in internal medicine
and that these side effects might be overlooked.A PSE
can be a stressful and traumatic life event for patients
and their families.For example,a person without known
psychiatric antecedents who develops a drug-induced
psychosis might suffer sequelae from the fear of having
lost their mind or from hospitalization in a psychiatric
ward. In given cases, a PSE might even lead to a post-
traumatic stress disorder,either because of the severity
of the PSE itself,or because of a deficient explanation of
the side effect to the patient.
Another issue is the importance of making a correct
diagnosis of a PSE.This is relevant for several reasons.
The main one is probably to help patients to make ade-
quate attributions and conclusions concerning their psy-
chological changes.Indeed,for someone who experiences
a PSE,knowing that it is a side effect has a different sig-
nification than wondering if oneself is mentally insane.
Detecting a PSE avoids its confusion with a sign of a psy-
chiatric disease;since spontaneous psychiatric diseases
frequently require long-term treatment,the correct diag-
nosis of a PSE can spare the patient the stigma,distress,
and other costs of an unjustified long-term psychiatric
treatment. Finally, the correct diagnosis of a PSE also
enables the prescriber to communicate suspected side
effects to the organization responsible for pharmacovig-
ilance. ❏ 
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Efectos secundarios psiquiátricos de los
medicamentos prescritos en medicina
interna
Varios tratamientos farmacológicos utilizados en
medicina interna pueden inducir efectos secunda-
rios psiquiátricos (ESP) que simulan diagnósticos
observados en psiquiatría. Los ESP se pueden pro-
ducir durante la retirada de un medicamento, por
una intoxicación y también cuando se utiliza en
dosis terapéuticas habituales. Entre los fármacos
que pueden inducir síndromes depresivos, ansiosos
o psicóticos están los corticoides, la isotretinoína, la
levodopa, la mefloquina, el interferon alfa y los
esteroides anabólicos, al igual que algunos medi-
camentos de venta libre. Los ESP a menudo son difí-
ciles de diagnosticar y pueden ser muy peligrosos
para los pacientes. En esta revisión se discuten los
ESP y también los elementos diagnósticos que faci-
litan su identificación.
Effets secondaires psychiatriques 
des médicaments prescrits en médecine
interne
Plusieurs traitements pharmacologiques en méde-
cine interne peuvent entraîner des effets secon-
daires psychiatriques (ESP) simulant des pathologies
vues en psychiatrie. Ces ESP peuvent survenir lors
du sevrage d’un médicament, lors d’intoxication ou
aux doses thérapeutiques usuelles. Parmi les médi-
caments qui peuvent induire des syndromes dépres-
sifs, anxieux ou psychotiques, on note les corti-
coïdes, l’isotrétinoïne, la lévodopa, la méfloquine,
l’interféron alpha et les stéroïdes anabolisants, tout
comme quelques médicaments en vente libre. Les
ESP sont souvent difficiles à diagnostiquer et peu-
vent être très délétères pour les patients. Cet article
passe en revue les ESP, ainsi que les éléments de
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